Health

ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001

*  Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform *  ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data *  ACM is in partnering d...

2023-09-05 14:00 1485

GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS)

* The first clinical trial sample analysis provider to adopt LIMS * To provide enhanced quality of pharmacokinetic, pharmacodynamic, and immunogenicity data from bioanalytic testing YONGIN, South Korea, Sept. 4, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, annou...

2023-09-05 09:57 1305

Game-changing Virtuoso Digital Front Door technology radically rewires healthcare

World-first technology launches to unlock preventative, proactive and predictive healthcare BOSTON, Sept. 4, 2023 /PRNewswire/ -- Global leader in population health, Orion Health, is ushering in the next era of health – moving from institution-centric reactive sick care to people-centered preven...

2023-09-04 21:00 1622

ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors

SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignan...

2023-09-02 00:00 3137

Adicon Holdings Limited (9860.HK): Continuous growth in Core Operations, Consistent Profitability Enhancement

HANGZHOU, China, Sept. 1, 2023 /PRNewswire/ -- Adicon Holdings Limited (the "Company" or "Adicon"), one of the largest independent clinical laboratory (ICL) service providers listed on the Stock Exchange ofHong Kong (SEHK), has released its interim results for the first half of 2023. As a leading...

2023-09-01 21:30 5543

Innovac Therapeutics Completes $18 million Series Pre-A Financing To Fund the Development of Its lead Programs and Manufacturing Capabilities

The funding represents a strong endorsement of Innovac's technology, mission and vision from a range of industry Investors BOSTON, SHANGHAI and HANGZHOU, China, Sept. 1, 2023 /PRNewswire/ -- Innovac Therapeutics, an mRNA therapeutics company, today announced the completion of an $18 million Seri...

2023-09-01 20:08 1640

usmile Revolutionizes Oral Care with the Launch of Y10 Pro Sonic Electric Toothbrush in the United States

Smart Screen, Responsive Brushing, and Smart Gum Care - The Future of Dental Hygiene HONG KONG, Sept. 1, 2023 /PRNewswire/ -- usmile, the oral care brand with the largest market share inAsia, proudly introduces its latest groundbreaking innovation to the American market - theY10 Pro sonic electr...

2023-09-01 19:22 1608

Peijia Medical Announces 2023 Interim Results

HONG KONG , Sept. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced financial results for the six months endedJune 30, 2023 ("the period...

2023-09-01 19:00 4520

Jin Medical (NASDAQ: ZJYL) Expands into the Manufacturing Field of lifestyle Beauty Products, Collaborates in Research and Development of Three Beauty and Body Products, Securing Market Orders

CHANGZHOU, China, Aug. 31, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("the Company" or "JinMed") (NASDAQ: ZJYL) is the world's leading provider of rehabilitation equipment. Recently, JinMed announcedit has expand into the field of manufacturing lifestyle beauty products by establishing ...

2023-08-31 22:37 1486

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023

BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative therapies for rare diseases...

2023-08-31 15:15 3891

Tycoon Group Announces 2023 Interim Results

The Group's Revenue Hits New Heights Net profit for 1H2023 increased more than 2.8 times YoY Benefited from the Full Resumption of Normal Travel Revenue Continues to Generate Profit in Future Results Highlights * Since the full resumption of normal travel between Hong Kong, Macau and Mainland C...

2023-08-31 13:28 3996

Zylox-Tonbridge's ZENFlow Tiger™ LD PTA Dilatation Catheter Receives ANVISA Marketing Approval

HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter (hereinafter referred to as "ZENFlow Tiger™"), a product independently ...

2023-08-31 11:31 1615

LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony'

* Announces Human Rights and Environmental Management Charter Alongside Annual Implementation Strategies within its Mid-to-Long-term ESG Roadmap * Strengthens Eco-friendly Policies, Including Greenhouse Gas Reduction Plans from the Initial Factory Design Stage SEOUL, South Korea, Aug. 30, 20...

2023-08-31 09:00 1697

Jacobio Pharma Announces 2023 Interim Results

BEIJING, SHANGHAI and BOSTON, Aug. 30, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced its 2023 interim results. During the period, the company recorded revenue ofRMB 40.3 million even as it continued to accelerate multip...

2023-08-30 21:45 3802

GC Biopharma to organize "Donate Blood with Love", a healthy way of giving back to the community

With the participation of all affiliated group entities YONGIN, South Korea, Aug. 30, 2023 /PRNewswire/ --All executives and employees of GC Biopharma, a South Korean biopharmaceutical company, rolled up their sleeves to practice ESG and social value. On Aug. 30th, the company held the "Donate...

2023-08-30 16:05 1324

Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Adm...

2023-08-30 14:19 1369

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors,announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approv...

2023-08-30 11:00 1749

Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure

SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue ofRMB21.395 bi...

2023-08-30 10:53 2679

Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF

—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit ofRMB2,489.5 million. —RMB2,915.2 million was recognized by Akeso as license fee income during the reporting period due to the receipt of an upfront payment equivalen...

2023-08-30 08:03 2218

Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development

SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised$32 million in Series A round of financing c...

2023-08-30 08:00 3596
1 ... 65666768697071 ... 272